AstraZeneca (AZN) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

AstraZeneca (AZN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

65.34

-0.39 (-0.59%)

At close: Jan 14, 2025, 3:59 PM

65.23

-0.17%

Pre-market Jan 15, 2025, 06:33 AM EST

undefined% (undefined)

Bid	65.2
Market Cap	202.60B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	2.08
PE Ratio (ttm)	31.41
Forward PE	n/a
Analyst	Buy

Ask	65.25
Volume	5,780,076
Avg. Volume (20D)	5,878,154
Open	65.17
Previous Close	65.73
Day's Range	64.22 - 65.66
52-Week Range	60.47 - 87.68
Beta	undefined

About AZN

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/...

[Show more]

Industry Drug Manufacturers - General

Sector Healthcare

IPO Date May 12, 1993

Employees 89,900

Stock Exchange NASDAQ

Ticker Symbol AZN

Website https://www.astrazeneca.com

Analyst Forecast

According to 8 analyst ratings, the average rating for AZN stock is "Buy." The 12-month stock price forecast is $85, which is an increase of 30.09% from the latest price.

Buy 75.00%

Hold 25.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

AstraZeneca is scheduled to release its earnings on Feb 6, 2025, before market opens.
Analysts project revenue of $14.14B, reflecting a 17.60% YoY growth and earnings per share of 1.1, making a 51.72% increase YoY.

Why Price Moved

2 months ago · Source

-7.22%

AstraZeneca shares are trading lower following a r... Unlock content with Pro Subscription

2 months ago · Source

+1.28%

AstraZeneca shares are trading higher. The European Union approved the company's Fasenra as an add-on treatment as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis.

News

22 hours ago · youtube.com

Trade Tracker: Jim Lebenthal buys Astrazeneca

Jim Lebenthal, chief equity strategist at Cerity Partners, joins CNBC's 'Halftime Report' to explain why he's buying the drugmaker.

2 days ago · seekingalpha.com

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...

2 days ago · zacks.com

Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

2 days ago · https://thefly.com

Compugen initiated with bullish view at Oppenheimer, here's why

Compugen +0.05 (+3.14%) AstraZeneca +0.44 (+0.66%) Gilead +0.7 (+0.79%)

2 days ago · businesswire.com

Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US fo...

2 days ago · businesswire.com

Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been acce...

6 days ago · fool.com

3 Cheap Growth Stocks to Buy in 2025

As we enter 2025, many growth stocks are trading at high valuations and could be running out of room to rise in the near term. For long-term investors, now may be a good time to reevaluate the content...

1 week ago · zacks.com

Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know

The latest trading day saw Astrazeneca (AZN) settling at $66.58, representing a -0.09% change from its previous close.

1 week ago · zacks.com

Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

1 week ago · businesswire.com

Deadline Approaching: AstraZeneca PLC (AZN) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming February 21, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who...

1 week ago · proactiveinvestors.com

J&J lung cancer treatment extends lives versus AstraZeneca drug

Johnson & Johnson (NYSE:JNJ) has said its chemotherapy-free combination extended lung cancer patients' lives compared to AstraZeneca PLC (LSE:AZN)'s Tagrisso drug in a head-to-head study. The combinat...